FDA Approves Tralokinumab for Atopic Dermatitis
- Author
- HCPLive.com
- Published
- Mon 10 Jan 2022
- Episode Link
- https://audioboom.com/posts/8010453
DocTalk returns in 2022 with a discussion of the recent Food and Drug Administration (FDA) approval of tralokinumab for the treatment of moderate-to-severe atopic dermatitis in adult patients.
For this episode, Jonathan Silverberg, MD, PhD, MPH, discusses the ECZTRA trials, 3 phase 3 trials that evaluated the efficacy of the biologic as a monotherapy as well as a combination therapy with topical corticosteroids.
Tralokinumab is the first and only biologic approved by the FDA that binds to and inhibits the interleukin (IL)-13 cytokine, noted as a key driver of signs and symptoms of atopic dermatitis. Dr. Silverberg speaks on what this new treatment means for the future of atopic dermatitis management.
For this episode, Jonathan Silverberg, MD, PhD, MPH, discusses the ECZTRA trials, 3 phase 3 trials that evaluated the efficacy of the biologic as a monotherapy as well as a combination therapy with topical corticosteroids.
Tralokinumab is the first and only biologic approved by the FDA that binds to and inhibits the interleukin (IL)-13 cytokine, noted as a key driver of signs and symptoms of atopic dermatitis. Dr. Silverberg speaks on what this new treatment means for the future of atopic dermatitis management.
